<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Etoposide</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00773</strong>&#160; (APRD00239)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits <span class="caps">DNA</span> synthesis by forming a complex with topoisomerase II and <span class="caps">DNA</span>. This complex induces breaks in double stranded <span class="caps">DNA</span> and prevents repair by topoisomerase II binding. Accumulated breaks in <span class="caps">DNA</span> prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00773/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00773/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00773.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00773.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00773.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00773.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00773.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00773">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>EPE</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>IS</td></tr><tr><td>EPEG</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Epipodophyllotoxin</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Etoposid</td><td>German</td><td>INN</td></tr><tr><td>Etoposide</td><td>French</td><td>INN</td></tr><tr><td>Etoposido</td><td>Spanish</td><td>INN</td></tr><tr><td>Etoposidum</td><td>Latin</td><td>INN</td></tr><tr><td>VP-16</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Etoposide Phosphate</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000070/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000070/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: LIQODXNTTZAGID-OCBXBXKTSA-N</li>
              <li>Monoisotopic Mass: 668.15062152</li>
              <li>Average Mass: 668.5365</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000070">DBSALT000070</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Eposin</td><td>medac</td></tr><tr><td>Etopofos</td><td>Bristol-Myers Squibb</td></tr><tr><td>Etopophos</td><td>Bristol-Myers Squibb</td></tr><tr><td>Lastet</td><td>Cancernova</td></tr><tr><td>Nexvep</td><td>Bristol-Myers Squibb</td></tr><tr><td>Toposar</td><td>Pfizer</td></tr><tr><td>Vepesid</td><td>Bristol-Myers Squibb</td></tr><tr><td>Vepesid K</td><td>Bristol-Myers Squibb</td></tr><tr><td>V&#233;p&#233;side</td><td>Novartis</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/antineoplastic-agents-phytogenic">Antineoplastic Agents, Phytogenic</a></li></ul></td></tr><tr><th>CAS number</th><td>33419-42-0</td></tr><tr><th>Weight</th><td>Average: 588.5566<br>Monoisotopic: 588.18429111</td></tr><tr><th>Chemical Formula</th><td>C<sub>29</sub>H<sub>32</sub>O<sub>13</sub></td></tr><tr><th>InChI Key</th><td>VJJPUSNTGOMMGY-MRVIYFEKSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C29H32O13/c1-11-36-9-20-27(40-11)24(31)25(32)29(41-20)42-26-14-7-17-16(38-10-39-17)6-13(14)21(22-15(26)8-37-28(22)33)12-4-18(34-2)23(30)19(5-12)35-3/h4-7,11,15,20-22,24-27,29-32H,8-10H2,1-3H3/t11-,15+,20-,21-,22+,24-,25-,26-,27-,29+/m1/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(10R,11R,15R,16S)-16-{[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-hexahydro-2H-pyrano[3,2-d][1,3]dioxin-6-yl]oxy}-10-(4-hydroxy-3,5-dimethoxyphenyl)-4,6,13-trioxatetracyclo[7.7.0.0^{3,7}.0^{11,15}]hexadeca-1(9),2,7-trien-12-one</div></td></tr><tr><th>SMILES</th><td><div class="wrap">[H][C@]12COC(=O)[C@]1([H])[C@H](C1=CC(OC)=C(O)C(OC)=C1)C1=CC3=C(OCO3)C=C1[C@H]2O[C@@H]1O[C@]2([H])CO[C@@H](C)O[C@@]2([H])[C@H](O)[C@H]1O</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Lignans and Norlignans</td></tr><tr><th>Class</th><td>Lignan Lactones</td></tr><tr><th>Subclass</th><td>Podophyllotoxins</td></tr><tr><th>Direct parent</th><td>Podophyllotoxins</td></tr><tr><th>Alternative parents</th><td>Arylnaphthalene Lignans; Tetralin Lignans; Tetralins; Methoxyphenols and Derivatives; Pyranodioxins; Benzodioxoles; Anisoles; Alkyl Aryl Ethers; 1,3-Dioxanes; Oxanes; Tetrahydrofurans; Oxolanes; Lactones; 1,2-Diols; Secondary Alcohols; Carboxylic Acid Esters; Polyamines; Acetals; Enols; Dialkyl Ethers</td></tr><tr><th>Substituents</th><td>arylnaphthalene lignan skeleton; tetralin lignan skeleton; methoxyphenol; tetralin; pyranodioxin; benzodioxole; anisole; phenol ether; alkyl aryl ether; phenol derivative; meta-dioxane; gamma butyrolactone; benzene; oxane; oxolane; tetrahydrofuran; secondary alcohol; 1,2-diol; lactone; carboxylic acid ester; ether; carboxylic acid derivative; polyamine; acetal; enol; dialkyl ether; alcohol</td></tr><tr><th>Classification description</th><td>This compound belongs to the podophyllotoxins. These are tetralin lignans in which the benzene moiety of the tetralin skeleton is fused to a 1,3-dioxolane and the cyclohexane is fused to a butyrolactone (pyrrolidin-2-one).</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.</td></tr><tr><th>Pharmacodynamics</th><td>Etoposide is an antineoplastic agent and an epipodophyllotoxin (a semisynthetic derivative of the podophyllotoxins). It inhibits DNA topoisomerase II, thereby ultimately inhibiting DNA synthesis. Etoposide is cell cycle dependent and phase specific, affecting mainly the S and G2 phases. Two different dose-dependent responses are seen. At high concentrations (10 &#181;g/mL or more), lysis of cells entering mitosis is observed. At low concentrations (0.3 to 10 &#181;g/mL), cells are inhibited from entering prophase. It does not interfere with microtubular assembly. The predominant macromolecular effect of etoposide appears to be the induction of DNA strand breaks by an interaction with DNA-topoisomerase II or the formation of free radicals.</td></tr><tr><th>Mechanism of action</th><td>Etoposide inhibits DNA topoisomerase II, thereby inhibiting DNA re-ligation. This causes critical errors in DNA synthesis at the premitotic stage of cell division and can lead to apoptosis of the cancer cell. Etoposide is cell cycle dependent and phase specific, affecting mainly the S and G2 phases of cell division. Inhibition of the topoisomerase II alpha isoform results in the anti-tumour activity of etoposide. The drug is also capable of inhibiting the beta isoform but inhibition of this target is not associated with the anti-tumour activity. It is instead associated with the carcinogenic effect. </td></tr><tr><th>Absorption</th><td>Absorbed well, time to peak plasma concentration is 1-1.5 hrs. Mean bioavailability is 50% (range of 25% - 75%). Cmax and AUC values for orally administered etoposide capsules display intra- and inter-subject variability. There is no evidence of first-pass effect for etoposide. </td></tr><tr><th>Volume of distribution</th><td><p>The disposition of etoposide is a biphasic process with a distribution half-life of 1.5 hours. It does not cross into cerebrospinal fluid well. <br>
Volume of distribution, steady state = 18 &#8211; 29 L.</p></td></tr><tr><th>Protein binding</th><td>97% protein bound. </td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Primarily hepatic (through O-demethylation via the CYP450 3A4 isoenzyme pathway) with 40% excreted unchanged in the urine. Etoposide also undergoes glutathione and glucuronide conjugation which are catalyzed by GSTT1/GSTP1 and UGT1A1, respectively. Prostaglandin synthases are also responsible for the conversion of etoposide to O-demethylated metabolites (quinone). </p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Etoposide</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li></ul></td><td><a href="/metabolites/DBMET00367">3'-demethyletoposide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/369">Details</a></td></tr><tr><td>Etoposide</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0003541" target="_blank">UDP-glucuronosyltransferase 1-1</a></li></ul></td><td><a href="/metabolites/DBMET00853">Etoposide glucuronide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/874">Details</a></td></tr><tr><td>Etoposide</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li>
<li><a href="/biodb/bio_entities/BE0002362" target="_blank">Cytochrome P450 3A5</a></li></ul></td><td><a href="/metabolites/DBMET01264">Etoposide catechol</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1424">Details</a></td></tr><tr><td><a href="/metabolites/DBMET01264">Etoposide catechol</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0001075" target="_blank">Myeloperoxidase</a></li></ul></td><td><a href="/metabolites/DBMET01265">Etoposide ortho-quinone</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1425">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Etoposide is cleared by both renal and nonrenal processes, i.e., metabolism and biliary excretion. Glucuronide and/or sulfate conjugates of etoposide are also excreted in human urine. Biliary excretion of unchanged drug and/or metabolites is an important route of etoposide elimination as fecal recovery of radioactivity is 44% of the intravenous dose. 56% of the dose was in the urine, 45% of which was excreted as etoposide. </td></tr><tr><th>Half life</th><td>4-11 hours</td></tr><tr><th>Clearance</th><td><ul>
	<li>Total body clearance = 33 &#8211; 48 mL/min [IV administration, adults]</li>
	<li>Mean renal clearance = 7 &#8211; 10 mL/min/m^2</li>
</ul></td></tr><tr><th>Toxicity</th><td>Side effects include alopecia, constipation, diarrhea, nausea and vomiting and secondary malignancies (leukemia).</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th></tr></thead><tbody><tr><td>Etoposide Action Pathway</td><td>Drug action</td></tr><tr><td>Etoposide Metabolism Pathway</td><td>Drug metabolism</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00601?highlight%5Bcompounds%5D%5B%5D=DB00773&amp;highlight%5Bproteins%5D%5B%5D=DB00773">SMP00601</a></td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.836</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              -
        </td>
        <td>0.9609</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.5234</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.7019</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8005</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8381</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8412</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8228</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9116</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.6134</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9045</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6884</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8392</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.529</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8309</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.5576</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.9132
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9325
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9467
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.9588 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9847
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.8734
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Mylan pharmaceuticals inc</li>
<li>Bristol myers squibb co</li>
<li>Accord healthcare inc usa</li>
<li>App pharmaceuticals llc</li>
<li>Bedford laboratories div ben venue laboratories inc</li>
<li>Hospira inc</li>
<li>Marsam pharmaceuticals llc</li>
<li>Pharmachemie bv</li>
<li>Pierre fabre medicament</li>
<li>Teva parenteral medicines inc</li>
<li>Watson laboratories inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.apppharma.com">APP Pharmaceuticals</a></li>
<li><a href="http://www.baxter.com">Baxter International Inc.</a></li>
<li><a href="http://www.bedfordlabs.com">Bedford Labs</a></li>
<li><a href="http://www.benvenue.com">Ben Venue Laboratories Inc.</a></li>
<li><a href="http://www.bms.com">Bristol-Myers Squibb Co.</a></li>
<li><a href="http://www.hospira.com">Hospira Inc.</a></li>
<li><a href="http://www.meadjohnson.com">Mead Johnson and Co.</a></li>
<li><a href="http://www.mylan.com">Mylan</a></li>
<li><a href="http://www.pfizer.com">Pfizer Inc.</a></li>
<li>Pharmachemie BV</li>
<li><a href="http://www.pharmaciaupjohn.com">Pharmacia Inc.</a></li>
<li><a href="http://www.rpscherer.de">R.P. Scherer GmbH and Co. KG</a></li>
<li>RP Scherer Canada Inc.</li>
<li>Sicor Pharmaceuticals</li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li>
<li><a href="http://www.udllabs.com">UDL Laboratories</a></li>
<li><a href="http://www.wyeth.com">Wyeth Pharmaceuticals</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule</td><td>Oral</td><td>50 mg </td></tr><tr><td>Injection, solution</td><td>Intravenous</td><td>20 mg/mL </td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00673">Aprepitant</a></td><td>Aprepitant may change levels of the chemotherapy agent, etoposide.</td></tr><tr><td><a href="/drugs/DB00091">Cyclosporine</a></td><td>Cyclosporine may increase the therapeutic and adverse effects of etoposide.</td></tr><tr><td><a href="/drugs/DB01369">Quinupristin</a></td><td>This combination presents an increased risk of toxicity</td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Telithromycin may reduce clearance of Etoposide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Etoposide if Telithromycin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00072">Trastuzumab</a></td><td>Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. </td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of etoposide by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of etoposide if voriconazole is initiated, discontinued or dose changed.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Grapefruit and grapefruit juice should be avoided throughout treatment as grapefruit can decrease serum levels of this product.</li></ul></td></tr></tbody></table>